Clinical Trial Update: Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 2/3 study evaluating Fruquintinib with or without hepatic artery infusion FOLFOX in patients with refractory colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• HAI-FOLFOX regimen

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer | Phase 2, Phase 3 | Status: RECRUITING